Primary Hyperparathyroidism and Gut Microbiota
Key facts
- Who runs it
- Centre Hospitalier Universitaire Vaudois
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 25 people enrolled
- Started
- 17 Nov 2021
- Ended
- 28 Feb 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- there will be no intervention, this is an observational study
- Record updated
- 13 April 2026
- Why it stopped
- not enough participants
Who can take part
- Age
- 30 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- diagnosis of primary hyperparathyroidism clinically established
- willing and able to give written informed consent
- age range 30-80 years
- commitment not to use any products that may influence the study outcome
- ability to understand and comply with the requirements of the study
Who cannot take part
- use of probiotic supplement within four weeks prior to baseline
- use within the past 8 weeks of medication with known influences on the immune or skeletal system
- use of antibiotics during the previous two months or frequent user of antibiotics
- type 1 and 2 diabetes mellitus
- renal or hepatic insufficiency
- history of any malignancies
- history of immunological or bone-related disorders
- impossibility to carry out DXA
- malabsorption
- alcohol abuse
- secondary hyperparathyroidism
- use of glucocorticoids or cinacalcet
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Primary hyperparathyroidism (PHPT) may induce bone loss according with the composition of the gut microbiota (GM), and particularly, on the presence of intestinal bacterial that induce T helper 17 differentiation.
Read full original descriptionShow less
We will evaluate GM composition and evaluate how GM modulates immune system in patients affected by PHPT with or without skeletal involvement. Furthermore, we will unravel the causal relationship between GM composition and T cells activation.
Upon success, HYPOGEUM will show that GM sequencing is a screening tool to identify PHPT that will lose bone, suggesting novel strategies with antimicrobial treatments to prevent bone loss.
HYPOGEUM will yield essential data to understand and prevent skeletal complications associated with PHPT.
The 2 groups in the trial
- not bone looser
patients affected by primary hyperparathyroidism not bone looser
Treatment: there will be no intervention, this is an observational study
- bone looser
patients affected by primary hyperparathyroidism bone looser
Treatment: there will be no intervention, this is an observational study
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Primary Hyperparathyroidism and Gut Microbiota Unravelling an Unexpected Relationship: the HYPOGEUM Study
- Record updated
- 13 April 2026